Cor.Con. International received the support of “Regione Emilia-Romagna” for the development of a new food supplement to treat side effects and comorbidities in epilectic subjects. The project was approved within the framework of the European Funds of the Emilia-Romagna Region – Por Fesr 2014-2020 and subsequently financed with resources of the Fund for Development and Cohesion FSC 2014-2020.
Epileptic subjects are affected by several comorbidities linked to the disease or to the use of drug therapies treating the epilectic disorders. These comorbidities or drug side effects are not usually treated properly, highly impacting on the patient’s quality of life and therapy compliance.
The most frequently encountered comorbidities are memory impairment, loss or attenuation of sense of self-worth, fatigue and tiredness, depression and sleep disorders. Comorbidities associated with the disease and antiepileptic therapy can greatly benefit from adjunctive and integrative treatments to alleviate non-neurological symptoms, promote a state of general well-being, and improve the therapy compliance.
On the basis of these considerations, Cor.Con. International aims to develop a new food supplement formulation based on physiological modulators acting on the aforementioned aspects.
The evaluation of clinical efficacy of the new formulation is currently ongoing in collaboration with the Pediatric Neurology and Muscular Diseases Unit of the IRCSS Giannina Gaslini and the Food and Drug Department of the University of Parma.